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Abstract
Background and Aims: Although genome-wide association studies [GWAS] in inflammatory bowel 
disease [IBD] have identified a large number of common disease susceptibility alleles for both 
Crohn’s disease [CD] and ulcerative colitis [UC], a substantial fraction of IBD heritability remains 
unexplained, suggesting that rare coding genetic variants may also have a role in pathogenesis. We 
used high-throughput sequencing in families with multiple cases of IBD, followed by genotyping 
of cases and controls, to investigate whether rare protein-altering genetic variants are associated 
with susceptibility to IBD.
Methods: Whole-exome sequencing was carried out in 10 families in whom three or more 
individuals were affected with IBD. A stepwise filtering approach was applied to exome variants, 
to identify potential causal variants. Follow-up genotyping was performed in 6025 IBD cases [2948 
CD; 3077 UC] and 7238 controls.
Results: Our exome variant analysis revealed coding variants in the NLRP7 gene that were present 
in affected individuals in two distinct families. Genotyping of the two variants, p.S361L and 
p.R801H, in IBD cases and controls showed that the p.S361L variant was significantly associated 
with an increased risk of ulcerative colitis [odds ratio 4.79, p = 0.0039] and IBD [odds ratio 3.17, 
p = 0.037]. A combined analysis of both variants showed suggestive association with an increased 
risk of IBD [odds ratio 2.77, p = 0.018].
Conclusions: The results suggest that NLRP7 signalling and inflammasome formation may be a 
significant component in the pathogenesis of IBD.
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1. Introduction
Genome-wide association scans [GWAS] have been very success-
ful in the identification of susceptibility genes for many common, 
complex disorders [https://www.ebi.ac.uk/gwas/]. GWAS in both 
major forms of inflammatory bowel disease [IBD], Crohn’s dis-
ease [CD] and ulcerative colitis [UC], have been among the most 
productive, and provided a better understanding of the biology 
of these diseases. There are now around 240 robust genetic asso-
ciations that have been identified1–3 in IBD. However, most asso-
ciations either span genomic regions that encompass multiple 
potential candidate genes or lie within non-coding or gene-poor 
regions. Their biological significance is therefore often unclear, 
and they explain only a modest proportion of the estimated her-
itability [or variation in genetic liability] of IBD. A  recent study 
by the International IBD Genetics Consortium used a fine-map-
ping approach in 67 852 individuals, in an attempt to pinpoint 
the true disease-causing DNA variants at 94 of the top IBD loci.4 
This identified 18 single independent causal DNA variants at 14 
loci with > 95% certainty, and 27 single independent genetic vari-
ants at 26 loci with > 50% certainty. Taken together, these 45 
independent associations at 37 loci were enriched for 13 variants 
which elicit changes specifically in the protein-coding sequences 
of seven genes.
It is thought that some of the hidden heritability in IBD may be 
explained by the association of rare protein-altering variants that 
are likely to confer a higher risk of disease. It is unlikely that such 
variants would be detected by the GWAS approach alone, which 
is designed to identify association with common variants. In re-
cent years, advances in DNA sequencing technology have facili-
tated gene sequencing on a much larger scale than could previously 
be attempted, enabling large-scale studies that have led to dis-
covery of complex disease-causing variants that previously eluded 
GWAS studies.5 Moreover, studies using targeted high-throughput 
sequencing of genes in IBD GWAS regions have, to date, detected 
around 30 multiple low-frequency variants associated with adult 
IBD6–10 in 17 genes, including multiple variants in the NOD2 and 
IL23R genes.
A recent UK IBD Genetics Consortium study has undertaken 
low-depth sequencing of the entire genome in 4280 IBD patients, 
and found only one new low-frequency protein-coding [missense] 
variant in the ADCY7 gene which increases risk for UC. However, 
this study also detected evidence for an increased ‘mutational-load’ 
of rare damaging missense variants in known CD risk genes, al-
though it was estimated that these low-frequency variants only 
accounted for a very small fraction of the variation in genetic li-
ability [heritability] of IBD [< 2%] in the general population.11 In 
general, the majority of genetic variants associated with common, 
complex disorders thus far do not lie within the coding regions of 
genes. However, this is not the case for some subsets of common dis-
orders with a strong familial predisposition, such as breast cancer 
and Alzheimer’s disease, in which rare, highly penetrant mutations 
have a causal role.
In this study, we hypothesised that families with large numbers 
of individuals affected with adult-onset IBD are more likely to have 
resulted from the action of rare or low-frequency damaging missense 
changes in one or a few genes. Such disease-causing variants would 
be easier to find by high-depth sequencing of coding genes in indi-
viduals from these families and, if present in genes from known IBD 
risk loci, might help to identify the causal genes in regions intractable 
to fine-mapping approaches.
2. METHODS
2.1. Subjects
A large collection of White British IBD families with three or more 
affected individuals were recruited, with informed consent and insti-
tutional ethical approval as described previously.12 Genomic DNA 
was prepared from 10  ml of whole blood using the salt/chloro-
form method described elsewhere.12 Ten families were selected for 
sequencing because they had more than three affected individuals 
across multiple generations. Overall, seven of the selected families 
were affected with only CD, two with only UC, and one family had 
both CD- and UC-affected individuals. DNA samples from a total of 
6025 IBD cases [2948 CD; 3077 UC] and 7238 controls of White 
British descent, described previously,9 were used for follow-up geno-
typing and association studies, as well as genotype data from 16 267 
UK IBD cases and 18 843 UK population controls from a recent 
whole-genome sequencing study.11
2.2. Exome sequencing analysis
Whole-exome sequencing [WES] was carried out on 27 affected indi-
viduals from ten families, that is, two, three, or four individuals from 
each family. Our sequencing strategy was devised so that, where pos-
sible, only the most distantly related and affected family members 
from each branch of each family were sequenced. Using this strategy, 
we assumed that rare or low-frequency variants, that were shared be-
tween the exome-sequenced affected relatives in a family, were highly 
likely to be identical by descent, therefore optimising the information 
gained against the cost of WES of all the affected individuals. A total of 
3 µg of genomic DNA was sheared to a mean fragment size of 150 bp 
[Covaris], and the fragments used for Illumina paired-end DNA li-
brary preparation and enrichment for target sequences [SureSelect 
Human All Exon 50Mb kit, Agilent]. Enriched DNA fragments were 
sequenced with 100-bp paired-end reads [GAIIx or HiSeq2000 plat-
form, Illumina]. Sequencing reads were aligned to the reference human 
genome sequence [hg19] using the Novoalign software [Novocraft 
Technologies]. Duplicate and multiply mapping reads were excluded, 
and the depth and breadth of sequence coverage were calculated using 
custom scripts and the BedTools package. Single-nucleotide substitu-
tions and small indels were identified with SAMtools, annotated with 
the ANNOVAR software, and variants called as previously described.13 
On average, seven gigabases of sequence were generated per sample; > 
82% of the target exome was present at > 20-fold coverage, and > 94% 
was present at > 5-fold coverage.
Identified variants were prioritised for follow-up based on the 
following filters.
i.  We assumed a dominant model of inheritance and therefore 
selected only those variants that were heterozygous,
ii.   We looked for variants most likely to have a functional effect/
be protein-altering, so we focused on non-synonymous [mis-
sense, nonsense, or canonical splice site substitutions], and 
variants that were absent or present with a frequency of < 1% 
in the Exome Aggregation Consortium database [ExAc] [http://
exac.broadinstitute.org/about] or whole-exome sequence data 
from > 1000 in-house non-IBD individuals.
iii.  We selected only those variants that were present in all WES 
members from each family, using the strategy described above.
iv.  Finally, to increase the likelihood of selecting disease-causing 
variants, we selected only those genes in which we had identi-
fied one or more variants fulfilling criteria i-iii above in at least 
two different IBD families.
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2.3. Pathogenicity prediction
A combination of three software tools─SIFT [http://sift.jcvi.org/], 
PolyPhen2 [http://genetics.bwh.harvard.edu/pph2/], and CADD14 
[http://cadd.gs.washington.edu/]─were applied to evaluate the 
pathogenicity of the 34 variants identified through our WES and fil-
tering strategy.
2.4. Sanger sequencing confirmation of NLRP7 
variants
The presence or absence of the rare NLRP7 variants detected by 
exome-sequencing was confirmed by Sanger sequencing in the 
same individuals as well as in additional available family mem-
bers who were either affected [two for family GS13, one for family 
GS64] or unaffected [seven for family GS13, five for family GS64] 
to test for co-segregation with IBD. Primers were designed using 
Primer3 software [http://primer3.sourceforge.net/]. Polymerase 
chain reaction [PCR] products were purified with ExoSAP-IT [GE 
Healthcare] and sequenced using BigDye Terminator v3.1 chemistry 
[Life Technologies] on a 3730xl DNA analyser [Life Technologies]. 
Sequence traces were visualised using the Sequencher 5.0 software 
[Gene Codes] and variants were detected by manual inspection of 
chromatograms.
2.5. Genotyping
Owing to sequence homology of the coding regions of NLRP7 
with its nearby paralogue NLRP2, the two rare variants in NLRP7, 
rs143169084 [p.S361L] and rs140797839 [p.R801H], detected 
by WES in IBD families, were genotyped using primers specifically 
designed to differentiate both paralogues [sequences available on 
request]. Genotyping assays were performed using the KASP chem-
istry at LGC Genomics [Hoddesdon, UK] in a further unrelated 
cohort of 6025 IBD cases [2948 CD and 3077 UC] and 7238 popu-
lation controls, to test for genetic association with IBD. Samples that 
failed to genotype for both single nucleotide polymorphisms [SNPs] 
were removed [102 CD, 132 UC, and 169 controls]. Genotype clus-
ters were visualised using SNPviewer [LGC genomics]. Carriage 
of the minor allele was confirmed by direct Sanger sequencing 
[as described above] in all identified IBD and control individuals 
within the genotyping cohort for p.S361L [n = 18] and p.R801H 
[n  =  5]. Asymptotic allelic case-control tests for association were 
performed using PLINK [http://pngu.mgh.harvard.edu/~purcell/
plink/]. Association P-values were corrected for multiple testing 
based on Bonferroni correction for six tests [two variants x three 
phenotypes].
The remaining 32 variants detected by WES and variant filtering 
were assessed for association with IBD using data from a recent UK 
whole-genome sequencing study and large GWAS meta-analysis of 
16 267 UK IBD cases and 18 843 UK population controls.11
3. Results
We conducted a screen for rare, potentially disease-causing coding 
variants by WES in a subset of the most distantly related affected 
individuals from 10 IBD families. The large number of coding vari-
ants that were identified across all individuals were prioritised for 
follow-up analysis by applying a series of stepwise variant filters.
First, within each family, we retained only those variants that were 
heterozygous, present in all WES-affected family members, and were pro-
tein-altering, i.e. those that introduce a missense, nonsense, or frameshift 
change in the protein structure or altered a canonical splice site, which 
left 21 127 variants. Next, we removed all common variants with an 
allele frequency reported to be equal to or greater than 1%. This filter-
ing strategy resulted in 694 variants identified in 627 genes including 
88 novel variants. Our final filter was to restrict the list of variants for 
follow-up to include only those genes that contained rare variants co-
segregating with IBD in WES individuals in two or more IBD families 
[see Methods], thus providing more than one source of evidence for the 
implicated gene.
This resulted in 34, low-frequency, protein-altering variants in 
17 genes responsible for a range of cellular functions including cell 
migration, metabolism, transcriptional activation, and the innate 
immune response [Supplementary Table 1, available as Supplementary 
data at ECCO-JCC online]. One of these genes, NLRP7, had a 
reported functional connection with immune-mediated disease 
and resided within one of the 240 mapped genetic regions associ-
ated with IBD1–3 [chromosome 19 at 55.4  Mb, hg19]. Our exome 
data had identified two missense variants within the NLRP7 gene, 
p.S361L [c.1082C>T, rs143169084] in family GS13, and p.R801H 
[c.2402G>A, rs140797839] in family GS64. The presence of these 
variants was validated by Sanger sequencing in the discovery cases, 
and further genotyped by Sanger sequencing in all available affected 
and unaffected members in the two families [Figure 1A]. In family 
GS13, p.S361L was present in all three affected family members with 
CD and in two unaffected individuals, and was absent in three unaf-
fected relatives and an unrelated spouse who coincidentally also has 
CD. This suggests that if p.S361L is the causal variant in this family, 
it is showing incomplete penetrance. In family GS64, the p.R801H 
variant was present in three of four affected relatives [two with CD; 
one with UC] and in one unaffected family member. The absence of 
p.R801H in one affected relative [Figure  1A] suggests that one or 
more other variants may have contributed to the development of 
IBD in this individual.
The two low-frequency NLRP7 variants were next followed up 
by genotyping in a large panel of 6025 unrelated IBD cases [exclud-
ing individuals from the families that underwent WES] and 7238 
population controls, to test for association with IBD. Both variants 
had a high call rate [> 99%] and were in Hardy–Weinberg equilib-
rium in both cases and controls. The minor A allele that encodes the 
variant leucine residue of NLRP7 p.S361L had a higher frequency 
in all IBD subgroups compared with controls [Freq[CD] = 0.100%, 
Freq[UC] = 0.200%, Freq[cont] = 0.035%] and was significantly associ-
ated with UC (P = 3.9 × 10-3, odds ratio [OR] = 4.79, 95% confi-
dence onterval [CI]: 1.60 - 14.00), also after correction for multiple 
testing [Table 1]. The minor T allele that encodes the variant histi-
dine residue of NLRP7 p.R801H also had a higher frequency in IBD 
cases compared with controls, but failed to achieve significance on 
its own [Table 1]. Owing to the low frequency of both of the variant 
alleles in the population, we performed a combined analysis of their 
cumulative frequency in IBD cases compared with controls, and this 
was significantly different, although not after correction for multiple 
testing (P = 0.018, Pcorrected = 0.054 [OR = 2.77, 95% CI: 1.14 - 6.75]) 
[Table 1].
The variant p.S361L maps to the NACHT domain of the NLRP7 
protein, whereas the p.R801H missense substitution is located in 
the leucine-rich repeat domain [Figure  1B]. The p.S361L variant 
was predicted to be ‘deleterious’ by the CADD pathogenicity soft-
ware tool [CADD score 23.4], ‘damaging’ by SIFT, and ‘probably 
damaging’ by PolyPhen-2. The p.R801H variant was predicted to 
be ‘tolerated’ [CADD score 13.99], ‘neutral’ by SIFT, and ‘benign’ 
by PolyPhen-2.
The remaining 32 variants in 16 genes that were identified by 
our WES and filtering strategy [Supplementary Table  1] were fol-
lowed up by examination of their frequency distribution in a recent 
large GWAS meta-analysis of 16 267 UK IBD cases and 18 843 UK 
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population controls.11 Of the 10 variants that were detected in the 
GWAS meta-analysis study and passed quality control, two showed 
evidence of association with IBD [P < 2 × 10-3]. These were both in 
the TRIM31 gene [Supplementary Table 1]. TRIM31 is located on 
chromosome 6p within the human major histocompatibility com-
plex [MHC] region. One of the associated variants, rs62624473, 
is a splice site substitution, and the minor allele [freq  =  0.9%] is 
associated with a decreased risk for UC and IBD [P  =  0.00174 
and 0.00172, respectively; OR  =  0.55 and 0.86, respectively] in 
the GWAS-meta analysis data. This is in contrast to the observed 
co-segregation of the rare allele with UC in family 107, suggesting 
that this variant is unlikely to be causal of disease. The second vari-
ant in TRIM31 is the missense change p.C48R, rs140451451. This 
variant is very rare [0.07%], but shows evidence of association with 
UC and IBD in the GWAS meta-analysis data [p = 2.82 × 10-05 and 
5.81 × 10-04, respectively]. It has a low CADD score [5.416], and 
is predicted to be ‘possibly damaging’ and ‘tolerated’ by SIFT and 
Polyphen2, respectively. Also, we cannot exclude the possibility that 
Table 1. Single and combined association analysis of the two protein-altering variants in the NLRP7 gene in 5801 inflammatory bowel 
disease cases and 7074 population controls.
p.S361L GG GA AA n MAF P Pcorrected Odds ratio 95%CI
CD 2846 3 0 2849 0.100% 0.8700 n.s. 1.49 0.35 - 6.20
UC 2942 10 0 2952 0.200% 0.0039 0.0234 4.79 1.60 - 14.00
IBD 5788 13 0 5801 0.110% 0.0370 n.s. 3.17 1.13 - 8.90
Control 7069 5 0 7074 0.035% - - -
p.R801H CC CT TT n MAF p p corrected Odds ratio 95% CI
CD 2804 2 0 2806 0.036% 0.6900 n.s. 2.40 0.35 - 17.68
UC 2945 1 0 2946 0.017% 1.0000 n.s. 1.18 0.10 - 13.08
IBD 5749 3 0 5752 0.026% 0.8000 n.s. 1.80 0.30 -10.90
Control 6984 2 0 6986 0.014% - - -
Combined 1/1 1/2 2/2 n Frequency p p corrected Odds ratio 95% CI
CD 2801 5 0 2806 0.18% n.s 1.77 0.56 - 5.6
UC 2935 11 0 2946 0.37% 0.003 0.009 3.73 1.44 - 9.63
IBD 5736 16 0 5752 0.28% 0.018 0.054 2.77 1.14 - 6.75
Control 6979 7 0 6986 0.10% - - -
CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; CI, confidence interval; n.s., not significant.
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Figure 1. [A] Segregation of the c.1082C>T [p.S361L] variant in pedigree GS13 and c.2402G> A [p.R801H] variant in pedigree GS64. [B] Location of the two 
protein-altering variants with respect to the functional domains of NLRP7; pyrin, NACHT and leucine-rich repeats [LRR].
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its association with IBD is a result of its correlation with common 
variants at the nearby HLA-DRB1 gene in the human MHC region, 
where there is known to be extensive linkage disequilibrium and 
multiple IBD-associated haplotypes.15
4. Discussion
Whole-exome sequencing of affected individuals in IBD families identi-
fied 17 genes in which rare coding variants were present in more than 
one family. None of these genes have thus far been found to be mutated 
in monogenic disorders associated with intestinal inflammation,16 
and only one, NLRP7, is located in one of the 240 loci known to be 
associated with IBD. This suggests that rare, highly penetrant, coding 
variants in genes from GWAS loci may not play a substantial role in 
the UK IBD families we have sequenced. The discovery of at least one 
significant association of a low-frequency coding variant in NLRP7 
[p.S361L] with IBD suggests that this and potentially other variants in 
this gene may predispose individuals to IBD. This is further supported 
by the prediction that p.S361L would damage the function of the 
NLRP7 protein. The NLRP7 variant p.R801H may be an incidental 
finding and not causally related to IBD in family GS64. However, the 
co-segregation of the variant allele with three of four individuals with 
the IBD phenotype in this family, and the association of both NLRP7 
variants with IBD in the combined analysis, warrant further explora-
tion of these and additional NLRP7 variants in very large case-control 
collections and additional IBD families.
The NLRP7 gene is located on chromosome 19 at position 
chr19:55,434,877-55,458,873 [hg19] within a known IBD locus. 
The region was initially identified by GWAS1 to be significantly asso-
ciated with IBD [p = 6.5 × 10-11], and spans multiple genes including 
NLRP7, NLRP2, KIR2DL1, LILRB4 and 15 others. The top asso-
ciated SNP in the region is rs11672983, although the two missense 
variants identified in this study are not in linkage disequilibrium 
with this SNP [r2 = 0]. This locus was not included in the recent fine-
mapping study by the International IBD consortium.4
Whereas NLRP7 variants were identified in families that con-
tained individuals affected by both CD and UC or by CD alone, we 
were able to detect a significant association signal only for p.S361L 
in UC. However, these findings do not preclude a role for NLRP7 
in CD. It is possible that the lack of association in this study may be 
because the effect size is smaller in CD [OR = 1.49] and thus lacked 
sufficient power to detect the smaller effect.
It has been reported that the p.S361L variant is more prevalent 
in the Ashkenazi Jewish [AJ] population [MAF = 0.0438] compared 
with White European populations [MAF = 0.0004] by the gnomAD 
database [http://gnomad.broadinstitute.org/]. This is of interest, as IBD 
is more prevalent in the AJ population17–19; however, there has been 
no reported association of NLRP7 or this region of chromosome 19 
with IBD in this population to date,20 and none of the IBD patients 
analysed in this association study had reported Jewish ancestry. The 
lack of an association of this variant with IBD in the Jewish popu-
lation could reflect the fact that NLRP7 variants are challenging to 
genotype because of homology with the nearby gene NLRP2, or that 
environmental components such as commensal bacteria and other fac-
tors that act through the NLRP7 pathway are also likely to play a 
substantial role in the aetiology of IBD in this population. The poten-
tial role of environmental factors is also consistent with the incomplete 
penetrance of the NLRP7 variants in families GS13 and GS64.
The NLRP7 gene encodes the NACHT, leucine-rich repeat and 
pyrin domain containing 7 protein, which is a member of the nucleo-
tide oligomerisation domain [NOD]-like receptor family of proteins. 
These are a family of pattern recognition receptors which include 
the known CD-risk gene NOD2 and are sensors of pathogen-asso-
ciated molecular patterns [PAMPs] involved in the innate immune 
response, apoptosis, and tissue damage. Over recent years there has 
been increasing evidence for the importance of these receptors in 
mucosal immunity21 and IBD,22 with colonic expression of a number 
of NLRs, including NLRP7, being shown to be significantly altered 
in patients with active IBD.22
NLRP7 expression is induced in response to LPS and IL-1β 
in peripheral blood mononuclear cells [PBMC] and is detected 
at high levels in thymus, spleen, and bone marrow, suggesting a 
role in host defence. NLRP3-mediated inflammasome assembly 
has been demonstrated to be important in both human and mouse 
models of IBD,23 and similarly it is known that the NLRP7 protein 
can promote both positive and negative regulation of inflamma-
some activity.24 For example, it is required for bacterial acylated 
lipoprotein-mediated caspase-1 activation and maturation of IL-1β 
and IL-18, but has also been shown to inhibit NLRP3 and caspase-
1-mediated IL-1β release. This contradiction may reflect a role for 
NLRP7 in preventing inflammasome formation and IL-1β release 
in quiescent cells while activating the inflammasome in response to 
bacterial infection.25 In either case, this would be consistent with the 
association of NLRP7 mutations with immune-mediated disorders 
such as IBD. Mutations in NLRP7 also contribute to the develop-
ment of hydatidiform mole in abnormal human pregnancies, which 
may involve inflammation-dependent or independent functions.26
In conclusion, we propose that rare coding variants in NLRP7 
may contribute to the development of IBD. Further work will be 
required to demonstrate the functional effects of these mutations in 
the context of intestinal inflammation, and to examine more gener-
ally the contribution of aberrant regulation of the inflammasome in 
the pathogenesis of IBD.
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